Andrew Huberman· PhD
But it, you know, separated from placebo and looks pretty good as well. It looks like it's, you know, the first of two trials that need to be done to get this thing approved for treatment resistant depression.
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
But it, you know, separated from placebo and looks pretty good as well. It looks like it's, you know, the first of two trials that need to be done to get this thing approved for treatment resistant depression.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
treatment resistant depression therefore is the indication siloc cybin is the intervention